4,833
Participants
Start Date
March 31, 2007
Primary Completion Date
September 30, 2011
Study Completion Date
December 31, 2011
Rivaroxaban (Xarelto, BAY59-7939)
During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
Enoxaparin overlapping with and followed by VKA
Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Taipei
Taipei
Lausanne
Lausanne
Auckland
Bruxelles - Brussel
Vienna
Budapest
Quezon City
Budapest
Vienna
Vienna
Bruxelles - Brussel
Genéve 14
Rud
Fredrikstad
Roodepoort
Auckland
Sydney
St Leonards
Johannesburg
Sydney
Kistarcsa
Johannesburg
Johannesburg
Kogarah
Sydney
Gosford
Lismore
Lier
Duffel
Garran
Leuven
Bern
Box Hill
Melbourne
Clayton
Melbourne
Geelong
Hasselt
Miskolc
Genk
Liège
Linz
Redcliffe
Brisbane
Debrecen
Woolloongabba
Southport
Palmerston North
Namur
Woodville South
Adelaide
Yvoir
Perth
Kecskemét
Lucerne
Innsbruck
Wellington South
Fremantle
Szentes
Feldkirch
Worcester
Chur
Trondheim
Szekszárd
Somerset West
Launceston
Cape Town
Aarhus C
Christchurch
Graz
Zurich
Brædstrup
Zalaegerszeg
Ghent
Aalst
Zottegem
Szombathely
Taipei
Tallinn
Jakarta
Pathumwan, Bangkok
Bangkok
Jakarta
Berlin
Prague
Safed
Pittsburgh
Girona
Camp Hill
Greifswald
Afula
Rozzano
Milan
Milan
Milan
Medan
Hamburg
Turku
Dijon
Varese
Baltimore
Fredericksburg
Besançon
Pavia
Vernon
Kladno
Rotenburg (Wümme)
Greensboro
Greensboro
Madrid
Piacenza
Brest
Venezia
Pamplona
Haifa
Haifa
Toulouse
Bordeaux
Paderborn
Miami
Tampere
Bay Pines
Castelnau-le-Lez
Montpellier
Haifa
Padua
Grenoble
Magdeburg
Bologna
Bandung
Taichung
Saint-Etienne
Reggio Emilia
Roanne
Parma
Nantes
Kfar Saba
Essen
Bottrop
Requena
Valladolid
Agen
Angers
Petah Tikva
Chiang Mai
Semarang
Vandœuvre-lès-Nancy
Mainz
Holon
Witten
Valenciennes
Frankfurt am Main
Frankfurt am Main
Arras
Clermont-Ferrand
Chesterfield
Tel Aviv
Darmstadt
Orthez
Chieti
Strasbourg
Kuala Selangor
Heidelberg
Heidelberg
Neckargemünd
Pierre-Bénite
Covington
Tübingen
Little Rock
Oklahoma City
Metz-Tessy
Paris
Paris
Paris
Paris
Paris
Rouen
Rehovot
Karlsbad
Bruchsal
San Antonio
Ashkelon
Amiens
München
München
Toulon
Idaho Falls
Murray
Salt Lake City
Augsburg
Limoges
Albuquerque
Palermo
Jerusalem
Clamart
Redlands
Colombes
Würzburg
Tacoma
Spokane
Nordhausen
Beijing
Beijing
Beijing
Beijing
Beijing
Beijing
Beijing
Shenyang
New Delhi
Harbin
Singapore
Shanghai
Shanghai
Shanghai
Suzhou
Singapore
Hangzhou
Pune
Wuhan
Hyderabad
Guangzhou
Guangzhou
Nanning
Kochi
Londrina
Miami
Boston
Chapel Hill
Les Escaldes
Rio de Janeiro
Guangzhou
Hong Kong
Wan Chai
Ballinasloe
London
Curitiba
Botucatu
São Paulo
São Paulo
São Paulo
São Paulo
Sorocaba
Winnipeg
London
Ottawa
Toronto
Toronto
Ostrava
Ostrava-Poruba
Prague
Prague
Rakovník
Usti Nad Lebem
Frederiksberg
Nice
Dresden
Halle
Liepāja
Kaunas
Vilnius
Amsterdam
Arnhem
Enschede
Groningen
Hoofddorp
Maastricht
Zwolle
Auckland
Oslo
Quezon City
Bialystok
Krakow
Lodz
Lublin
Poznan
Poznan
Torun
Warsaw
Wroclaw
Wroclaw
San Juan
Pretoria
Pretoria
Pretoria
Seoul
Daegu
Seoul
Taegu
Barcelona
Barcelona
Terrassa
Palma de Mallorca
Borås
Gothenburg
Gothenburg
Jönköping
Stockholm
Sundsvall
Plymouth
Isleworth
London
London
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
Bayer
INDUSTRY